How pharma marketers can reclaim the drug pricing narrative
PharmaVoice
SEPTEMBER 28, 2023
As Medicare negotiations heat up, it’s more important than ever for pharma companies to communicate their value. Here’s how.
STAT+: Senator launches investigation into GSK’s asthma inhaler maneuvers
STAT
JUNE 27, 2025
And so Hassan called on GSK to return the product to market and, meanwhile, asked for numerous documents concerning pricing, rebates and communications with regulators. This marks the second time in recent months that GSK has angered a lawmaker over the asthma inhaler switch. In March, U.S. Elizabeth Warren (D-Mass.)
Documentation 
198
198 Join 11,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
STAT+: Europe takes steps to head off drug shortages, even as U.S. proposals stall
STAT
OCTOBER 25, 2023
There were also shortages of heart drugs. big proposals to solve the drug shortages have made little progress so far. On Tuesday, though, in a so-called Communication , the European Medicines Agency issued guidelines aimed at providing relief from shortages. In the U.S., Continue to STAT+ to read the full story…
Communication 300
300 
Pharma Pulse 5/2/24: The Impact of IRA on Drug Prices and Patient Access, Early Communication Crucial for Successful Drug Launch & more
Pharmaceutical Commerce
MAY 2, 2024
The latest news for pharma industry insiders.
Drug Pricing 104
104 
Okra says AI-based drug price predictor is 90% accurate
pharmaphorum
NOVEMBER 30, 2020
Okra has also developed AI platforms to make sales reps’ workflows more efficient, predict sales volumes for products, and improve communications between medical scientific liaisons (MSLs) and healthcare practitioners. The post Okra says AI-based drug price predictor is 90% accurate appeared first on.
Drug Pricing 64
64 
NHC Submits Comments on CMS Draft Guidance for IPAY 2028
Putting Patients First Blog
JUNE 26, 2025
The NHC supports the efforts to reduce out-of-pocket costs for Medicare beneficiaries and appreciates CMS’ work to establish a process that seeks to incorporate patient perspectives into drug pricing policy. Even well-intentioned policies can create access disparities if communication and operational support are lacking.
Drug Pricing 52
52 
Educating Patients about Generic Drugs: Strategies for Success
Drug Patent Watch
JANUARY 7, 2025
The Importance of Generic Drugs in Healthcare Generic drugs offer several benefits to patients and the healthcare system: Cost-effectiveness: Generic drugs are typically much cheaper than brand-name medications, making treatment more accessible to patients. Remember, patient education is an ongoing process.
Why 2025 Will Be a Breakout Year for Pharma Marketing Innovation
Pharma Marketing Network
APRIL 28, 2025
Additionally, regulatory bodies like the FDA are encouraging patient-focused communications, further legitimizing this trend. The Inflation Reduction Act and new drug pricing regulations are pushing pharmaceutical companies to justify value more transparently.
NHC Comments on Negotiation Data Elements and Drug Price Negotiation Process for Initial Price Applicability Year 2027 under Sections 11001 and 11002 of the IRA ICR Forms
Putting Patients First Blog
SEPTEMBER 3, 2024
Overall, while the NHC appreciates CMS’ intent to streamline the data submission process and make it more accessible, we encourage ongoing dialogue and adjustments to ensure that the process remains patient-centered, efficient, and capable of capturing the full spectrum of information necessary to inform meaningful drug price negotiations.
Drug Pricing 52
52 
Potential impact of Pharma Tariffs on Marketing
Pharma Marketing Network
APRIL 1, 2025
Elevated prices can lead to decreased affordability and reduced patient adherence, prompting marketers to adjust their branding and value propositions strategically. Pharma marketers must ensure transparent communication with healthcare providers, patients, and insurers about pricing changes influenced by pharma tariffs.
Is Big Pharma A Negative Term for Marketing?
Pharma Marketing Network
APRIL 20, 2025
Criticisms typically revolve around drug pricing, lobbying influence, and perceived lack of access in underserved communities. Be proactive in communication. Whether its announcing changes in pricing, access programs, or patient support tools, keeping stakeholders informed enhances credibility. Its central.
Labelling 52
52 
Changing the PAP Model
Pharmaceutical Commerce
JUNE 17, 2025
Given the strict state and federal regulations governing how manufacturers communicate with or support patients, companies face significant legal and regulatory risk when managing PAP programs.
RFK Jr looks to alter rare disease regulation by fast-tracking drug approvals
Pharmaceutical Technology
JUNE 6, 2025
We may still continue to send you service-related and other non-promotional communications. By Cytiva Thematic You have a right to withdraw your consent at any time, by clicking here. For more information relating to our privacy practices, we invite you to review our privacy policy. Sign up for our daily news round-up!
Effective Drug Patent Prosecution Strategies: Securing Your Pharmaceutical Innovations
Drug Patent Watch
DECEMBER 18, 2024
It’s all about clear communication and finding common ground with the examiner.” ” Maximizing Patent Term Given the long development timelines for drugs, maximizing your patent term is crucial. Balancing Profit and Public Health Pharmaceutical companies face increasing scrutiny over drug pricing and access.
Mosanna Therapeutics gains $80m to advance OSA nasal spray
Pharmaceutical Technology
JUNE 10, 2025
Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Give your business an edge with our leading industry insights.
MSD receives FDA approval for Enflonsia to prevent RSV
Pharmaceutical Technology
JUNE 10, 2025
Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Give your business an edge with our leading industry insights.
FDA approves YolTech’s YOLT-101 for familial hypercholesterolemia
Pharmaceutical Technology
JUNE 9, 2025
Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Give your business an edge with our leading industry insights.
5 ways digital health, and digital pharma, changed in 2020
pharmaphorum
DECEMBER 24, 2020
Now, after a year that feels like it had many more than the usual 12 months, ‘digital’ has most certainly come of age across all aspects of our lives, including communication , commerce, working life and, yes, health. So, what were the standout changes for digital health, and digital pharma for that matter, in this most unusual of years?
Drug Pricing 126
126 
NHC Comments on Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 – 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027
Putting Patients First Blog
JULY 2, 2024
General Comments The NHC appreciates CMS’ commitment to actively engaging with stakeholders, including patients, consumer advocates, and health experts, in implementing the Medicare Drug Price Negotiation Program (DPNP). We commend CMS for its commitment to improving these sessions and provide the following detailed recommendations.
Drug Pricing 52
52 
Juvenescence enhances AI drug discovery with Ro5 acquisition
Pharmaceutical Technology
JUNE 6, 2025
Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Give your business an edge with our leading industry insights.
EC authorises Sydnexis’ paediatric myopia treatment
Pharmaceutical Technology
JUNE 6, 2025
Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Give your business an edge with our leading industry insights.
Aytu BioPharma to commercialise Exxua for MDD in the US
Pharmaceutical Technology
JUNE 9, 2025
Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Give your business an edge with our leading industry insights.
SCHOTT Pharma invests in RTU cartridge capacity expansion
Pharmaceutical Technology
JUNE 6, 2025
Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Give your business an edge with our leading industry insights.
Navigating 340B Program Changes in 2025
Proxsys Rx
APRIL 1, 2025
Regardless of your answer, theres no question the 340B Drug Pricing Program remains a critical resource for eligible healthcare providers, enabling them to stretch scarce federal resources to provide essential services to underserved communities.
The European Market Access Lag: 2021–2024
Pharmaceutical Technology
JUNE 9, 2025
Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Give your business an edge with our leading industry insights.
The Brazilian pharma market: Key information and what may change
Pharmaceutical Technology
DECEMBER 9, 2022
There are also strict price controls, which in some cases can limit profitability for manufacturers. Brazilian public spending on healthcare, drug pricing reforms and remote medicine. Despite this, Brazil’s trade protectionist policies mean that there are few pharmaceutical companies of international origin within the country.
Drug Pricing 98
98 
Inflationary storm clouds will continue to buffet global pharma industry in 2023
Pharmaceutical Technology
JANUARY 16, 2023
The topic of inflation overlaps with drug pricing strategy themes. Policymakers are attempting to respond to inflation crises by introducing new frameworks on the regulation of drug prices. Similar echoes are heard in Europe, where pressure to curb price growth will stay a priority.
Drug Pricing 64
64 
Year in Review: Top Regulatory Developments of 2024
Big Molecule Watch
JANUARY 10, 2025
The updated guidance includes information on the general requirements for the content of FDA-regulated promotional communications about reference or biosimilar products and provides some examples to illustrate the FDAs current recommendations for addressing reference, biosimilar, and interchangeable biosimilar products in product promotion.
Biosimilars 45
45 
Achieving scale up success under economic uncertainty
European Pharmaceutical Review
SEPTEMBER 14, 2023
Market uncertainty Rising operational costs, stiffening competition, ongoing patent expirations, evolving environmental and social governance requirements and increasing pressure on drug prices mean the industry will have to navigate thoughtfully to be successful amid this complicated mix of financial and strategic risks.
Specialized Software Can Only Do So Much For 340B Programs
Proxsys Rx
OCTOBER 6, 2022
That’s why helping health systems minimize data mismatches at the source is so critical to maximizing 340B savings 340B drug pricing program savings for a covered entity — and why meeting that challenge is a core component of our 340B software and service package. There are many places where communication failures can and do occur.
Hospitals 52
52 
Inflationary storm clouds will continue to buffet global pharma industry in 2023
Pharmaceutical Technology
JANUARY 16, 2023
The topic of inflation overlaps with drug pricing strategy themes. Policymakers are attempting to respond to inflation crises by introducing new frameworks on the regulation of drug prices. Similar echoes are heard in Europe, where pressure to curb price growth will stay a priority.
Drug Pricing 52
52 
2022 spells change for EU pharmaceutical legislation
European Pharmaceutical Review
JUNE 24, 2022
The review was impacted by Brexit and the COVID-19 pandemic, which compounded existing issues surrounding high drug pricing and patient access that had been brewing since 2016 and highlighted several shortcomings in the EU’s pharmaceutical system. It is too early to say because we have not seen the whole package of measures yet.
Compounding 105
105 
Coherus allies with Mark Cuban to challenge AbbVie for Humira biosimilar
Pharmaceutical Technology
JUNE 2, 2023
In a bit to challenge the market dominance of AbbVie’s Humira (adalimumab), the online pharmacy Cost Plus Drugs, owned by billionaire Mark Cuban has announced a plan to market Coherus Biosciences’ biosimilar Yusimry (adalimumab-aqvh), Cost Plus Drugs will be offering Yusimry at $569 per unit, excluding shipping and dispensing charges.
Biosimilars 52
52 
“Out Of Storage”: How Cognitive Load Theory Could Help Us Rethink Teaching Strategies
Pulses
JANUARY 9, 2024
This topic could be informative in how we approach curricular design, student success, communication strategies, and college/school work and learning environments overall.
Drug Pricing 64
64 
Exforge antitrust settlement caps Novartis’ year of legal disputes
Pharmaceutical Technology
JANUARY 6, 2023
The alleged actions violated the Hatch-Waxman Act, formally known as the “Drug Price Competition and Patent Term Restoration Act of 1984,” which allows generic manufacturers to market their generic versions of previously approved generic medications. These actions allegedly led to the extension of Novartis’ patents.
“Out Of Storage”: How Cognitive Load Theory Could Help Us Rethink Teaching Strategies
Pulses
JANUARY 9, 2024
This topic could be informative in how we approach curricular design, student success, communication strategies, and college/school work and learning environments overall.
Drug Pricing 52
52 
Three strategies for managing loss of exclusivity successfully
pharmaphorum
FEBRUARY 18, 2021
Drug prices to plummet in wave of expiring patents”. Price decay after loss of brand exclusivity”. These are just three headlines that come up when you Google “drug patent expiry”. Do not try and adapt your strategy to be a generic strategy – although price is important and difficult to compete against, don’t fight it.
Asian Pharma Stocks Dropping As US Cuts Drug Prices
Pharma Marketing Network
MAY 11, 2025
accelerates its crackdown on drug pricing through new legislation and regulatory enforcement, pharma companies in China, India, Japan, and South Korea are feeling the ripple effect. This move marked a major shift in how drug pricing is managed in the United Statesa market that contributes significantly to global pharma revenues.
Drug Pricing 59
59 
Building a Pharmacy Culture You’re Proud Of
pharmacy mentor
JANUARY 15, 2023
Foster open communication and transparency Encourage sharing ideas, concerns, and feedback openly and honestly throughout your team. We understand that life in Community Pharmacy is usually high-speed, and can be very stressful. People follow leaders for their passion and because they align with their vision.
How to Seize New Pharmacy Opportunity in the Pharma Industry
The Nontraditional Pharmacist
NOVEMBER 20, 2019
Another area is a medical communication and scientific communications, which also includes publication planning. And once a communications plan in terms of what should be communicated and then what we call the scientific platform when it gets developed for a product or a device, etc.
How early planning leads to successful market access and drug launch in Europe
Pharmaceutical Technology
FEBRUARY 7, 2023
An example is NICE’s Quality Adjusted Life Year score, used to price drugs in the UK. Some nations such as France base their decisions on the drug’s medical benefit and clinical added value versus existing therapies. Please check your email to download the Case Study.
FDA approves KalVista’s Ekterly for hereditary angioedema
Pharmaceutical Technology
JULY 7, 2025
Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. How will RFK Jr’s American dream for vaccines play out?
Packaging 122
122 
Novavax is on thin ice, and the latest update isn’t exactly encouraging
STAT
FEBRUARY 1, 2024
Biotech can’t shake the Fed The XBI, a closely watched index of biotech stocks, turned red for the year yesterday, and not because of a clinical disappointment, a drug pricing scandal, or an M&A rumor that came to nothing. In 2024, as in 2023, the industry’s fate seems inextricable from interest rates.
Drug Pricing 302
302 
NHC Comments on IRA Guidance Response
Putting Patients First Blog
APRIL 14, 2023
10: External Data Submission Timing The NHC understands the tight timeline for the drug selection and price negotiation processes. Created by and for patient organizations over 100 years ago, the NHC brings diverse organizations together to forge consensus and drive patient-centered health policy.
Drug Pricing 40
40 
Let's personalize your content